ABVC (ABVC BioPharma) Moat Score: 2/10 (As of Jun. 26, 2026)


ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.46
GF Value $0.87
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Moat Score?

ABVC BioPharma ABVC +1.39% 17 Moat Score is 2 as of Jun. 26, 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, ABVC BioPharma ranks better than 58.12% on this metric.

ABVC BioPharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

ABVC BioPharma has No Moat: ABVC BioPharma Inc operates in a competitive biotech industry with no significant market share or customer loyalty. The company lacks strong intellectual property, regulatory barriers, or cost advantages, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ABVC BioPharma might have No Moat - Very weak/transient advantages.

ABVC BioPharma  (NAS:ABVC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ABVC BioPharma Moat Score Related Terms

ABVC vs GRDX, INMB, ALGS: Moat Score Comparison

For the Biotechnology subindustry, ABVC BioPharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABVC BioPharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Moat Score distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Moat Score falls into.


ABVC
17GF Score
ABVC BioPharma Inc ABVC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
ABVC BioPharma (ABVC) has a Moat Score of 2 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, ABVC BioPharma ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is ABVC BioPharma's Moat Score too high?
ABVC BioPharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. ABVC BioPharma's value of 2 is 0% at this industry median. Based on the distribution chart, ABVC BioPharma ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Moat Score compare to GRDX and INMB?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #588 out of 1404 companies for Moat Score. This puts ABVC BioPharma in the upper half of its industry. The industry median Moat Score is 2.00. ABVC BioPharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABVC BioPharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.46 — trading 67.8% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Moat Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABVC BioPharma (ABVC) Overvalued in 2026?

Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued. The current stock price of $1.46 is trading 67.8% above its estimated GF Value™ of $0.87. GuruFocus considers ABVC BioPharma to be Significantly Overvalued.

Key valuation signals for ABVC:

  • Moat Score: 2
  • GF Value™: $0.87 vs. price of $1.46 (67.8% above fair value)
  • GF Score™: 17/100 with 1 warning sign
  • Industry Position: 0% at the Biotechnology median (#588 of 1404)

No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score

Get the complete analysis for ABVC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$0.87
GF Value